GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » Capex-to-Operating-Income

Cytek Biosciences (Cytek Biosciences) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Cytek Biosciences's Capital Expenditure for the three months ended in Mar. 2024 was $-0.62 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-10.73 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Cytek Biosciences Capex-to-Operating-Income Historical Data

The historical data trend for Cytek Biosciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences Capex-to-Operating-Income Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
0.35 0.11 0.48 - -

Cytek Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cytek Biosciences's Capex-to-Operating-Income

For the Medical Devices subindustry, Cytek Biosciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytek Biosciences's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's Capex-to-Operating-Income falls into.



Cytek Biosciences Capex-to-Operating-Income Calculation

Cytek Biosciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-4.827) / -27.845
=N/A

Cytek Biosciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.622) / -10.734
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytek Biosciences  (NAS:CTKB) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Cytek Biosciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytek Biosciences (Cytek Biosciences) Business Description

Traded in Other Exchanges
Address
47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance.
Executives
Patrick Jeanmonod officer: Chief Financial Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Ming Yan director, officer: Chief Technology Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang director, officer: President and CEO C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque officer: SVP, Global Sales and Services 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams officer: Chief Operating Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison director
Deborah J Neff director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron director C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng director SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116